Produktbild
Michel (Hrsg.) Burnier

Drug Adherence in Hypertension and Cardiovascular Protection

Buch

This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood p… Mehr

CHF 150.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen

Produktdetails


  • ISBN: 978-3-030-09528-4
  • EAN: 9783030095284
  • Produktnummer: 31957591
  • Verlag: Springer Nature EN
  • Sprache: Englisch
  • Erscheinungsjahr: 2019
  • Seitenangabe: 314 S.
  • Masse: H23.5 cm x B15.5 cm 670 g
  • Auflage: Nachdr.
  • Abbildungen: schwarz-weiss Illustrationen, farbige Illustrationen, Tabellen, farbig
  • Gewicht: 670
  • Sonstiges: Professional/practitioner

Über den Autor


Michel Burnier is Professor of Medicine and head of the Nephrology and Hypertension Consultation division at the University Hospital of Lausanne, Switzerland. He trained in internal medicine and nephrology in Lausanne, Switzerland and at the University of Colorado Health Science Centre in Denver, Colorado. He is a member of the Scientific Council of the European Society of Hypertension and member of the Committee of the Swiss Society of Hypertension. He was president of the Swiss Society of Nephrology and of the Swiss Society of Hypertension. Burnier is a member of the editorial board of several international journals in the field of hypertension and nephrology. His research interests are the renal mechanisms of hypertension and the pathogenesis of disease progression in chronic kidney diseases with an emphasis on the role of sodium. He has also worked on the clinical pharmacology of new antihypertensive drugs in humans with a focus on drugs affecting the renin-angiotensin system and on drug adherence. In 2010, he received the JM Métry Compliance Award of the ESPACOMP, the European Society of Drug Adherence.

2 weitere Werke von Michel (Hrsg.) Burnier:


Bewertungen


0 von 0 Bewertungen

Geben Sie eine Bewertung ab!

Teilen Sie Ihre Erfahrungen mit dem Produkt mit anderen Kunden.